Predictors of the composite cardiovascular outcome in NAVIGATOR participants as identified in a multivariable Cox proportional hazard stepwise selection model
| Variable | HR (95% CI) | Wald χ² | p Value |
|---|---|---|---|
| Coronary heart disease* | 2.10 (1.76 to 2.50) | 68.8 | <0.0001 |
| Gender (male vs female) | 1.89 (1.55 to 2.29) | 40.9 | <0.0001 |
| Age (per 10 years) | 1.32 (1.17 to 1.48) | 21.4 | <0.0001 |
| Current smoker | 1.64 (1.32 to 2.04) | 19.5 | <0.0001 |
| Significantly abnormal vs normal ECG | 1.59 (1.28 to 1.97) | 17.6 | <0.0001 |
| LDL cholesterol | 1.19 (1.09 to 1.30) | 15.9 | <0.0001 |
| Cerebrovascular disease* | 1.56 (1.25 to 1.95) | 15.5 | <0.0001 |
| eGFR (per 10 unit decrease below 60 ml/min/1.73 m2) | 1.31 (1.13 to 1.51) | 12.6 | 0.0004 |
| Peripheral artery disease* | 1.65 (1.24 to 2.19) | 11.6 | 0.0007 |
| Pulmonary embolism/deep vein thrombosis | 2.12 (1.36 to 3.31) | 10.9 | 0.0010 |
| Urine albumin/creatinine ratio (log units) | 1.10 (1.03 to 1.17) | 9.1 | 0.0025 |
| Latin America vs North America | 1.48 (1.15 to 1.92) | 9.0 | 0.0027 |
| Pulse pressure (per 1 mm Hg) | 1.01 (1.00 to 1.01) | 7.8 | 0.0051 |
| Chronic obstructive pulmonary disease | 1.44 (1.10 to 1.88) | 7.1 | 0.0077 |
| Black vs all other races | 1.75 (1.13 to 2.71) | 6.3 | 0.0123 |
| Heart failure | 1.43 (1.07 to 1.90) | 5.9 | 0.0150 |
| Haemoglobin (per 10 g/l decrease) | 1.09 (1.02 to 1.16) | 5.8 | 0.0158 |
| Sodium (1 unit decrease below 140 mmol/l) | 1.11 (1.02 to 1.20) | 5.5 | 0.0185 |
| Waist circumference (per 10 cm) | 1.08 (1.01 to 1.15) | 5.4 | 0.0197 |
| Atrial fibrillation or flutter | 1.34 (1.01 to 1.79) | 4.0 | 0.0463 |
| Other vs North America | 1.40 (0.91 to 2.15) | 2.3 | 0.1285 |
| Insignificantly abnormal vs normal ECG | 1.11 (0.91 to 1.35) | 1.1 | 0.3000 |
| Europe vs North America | 0.92 (0.74 to 1.14) | 0.6 | 0.4391 |
| Asia vs North America | 0.90 (0.59 to 1.37) | 0.2 | 0.6268 |
*For definitions see table 1 footnote.
eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; NAVIGATOR, Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research.